Published: May 25, 1999Received: -Available on J-STAGE: June 28, 2010Accepted: -
Advance online publication: -
Revised: -
Correction information
Date of correction: June 28, 2010Reason for correction: -Correction: KEYWORDDetails: [in Japanese]
Date of correction: June 28, 2010Reason for correction: -Correction: CITATIONDetails: Wrong : E E E E E E E E E E E E E E E E E E
Right : 1)Okamoto S, Hijikata A, Kikumoto R, et al: Potent inhibition of thrombin by the newly synthesized arginine derivative No 805, Theimportance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun,101;440-446,1981. 4)Davies D C, Salzman E W, Sobel M: Elevatedfebrinopeptide A and thromboxane A 2 levels during cardiopulmonary bypass. Curculation, 61; 805-814, 1980. 5)Brister SJ, Ofosu FA, Buchanan MR: Throm bin genaration during cardiac surgery is heparin the ideal anticoagulant?: Thromb Haemost, 70;259-262,1993. 7)Kumada T,Abiko Y: Comparative study on heparin and a synthetic thrombin inhibit or No805(MD-805) in experimental antithronbin III deficcient animals. Thromb Res, 24; 285, 1981. 8)Kawada T, Mieda T, Hoson M,et al: Left heart bypass with the Bio-Medicus centrifugal pump-the use of argatroban for preventing platelet loss. Artif Organs Today, 2; 177-187, 1992. 13)Egeberg O: Inherited antithrombin deficiency casing thrombophilia.Thromb Diath Haemorrh, 13; 516, 1965. 17)Boonstra PW, Gu YJ,Van Oeveren W, et al: Heparine coating of an extracorporeal circuit partly improves hemostasis after cardiopul monary bypass. J Thorac Cardiovasc Surg,107;289-292,1994. 18)Von Segesser LK, Weiss BM, Turina MI, et al: Reduction and elimination of systemic heparinnization during cardiopulmonary bypass. J Thorac Cardiovasc Surg, 103; 790-799,1992.